CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 116 filers reported holding CRINETICS PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $5,275,073 | +679.0% | 177,373 | +372.0% | 0.00% | – |
| Q2 2023 | $677,138 | +9.8% | 37,577 | -2.2% | 0.00% | – |
| Q1 2023 | $616,865 | +84.4% | 38,410 | +110.1% | 0.00% | – |
| Q4 2022 | $334,543 | -8.6% | 18,281 | -2.0% | 0.00% | – |
| Q3 2022 | $366,000 | -6.2% | 18,647 | -10.9% | 0.00% | – |
| Q2 2022 | $390,000 | -8.2% | 20,919 | +8.1% | 0.00% | – |
| Q1 2022 | $425,000 | -92.1% | 19,343 | -89.8% | 0.00% | -100.0% |
| Q4 2021 | $5,404,000 | +1457.3% | 190,235 | +1052.9% | 0.00% | – |
| Q3 2021 | $347,000 | +34.5% | 16,501 | +20.4% | 0.00% | – |
| Q2 2021 | $258,000 | – | 13,702 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Saturn V Capital Management LP | 623,819 | $11,336,501 | 9.41% |
| Finepoint Capital LP | 822,745 | $15,056 | 4.87% |
| Bain Capital Life Sciences Investors, LLC | 2,305,558 | $42,192 | 4.72% |
| Opaleye Management Inc. | 732,000 | $13,395,600 | 4.66% |
| 5AM Venture Management, LLC | 862,286 | $15,779,834 | 4.24% |
| SPHERA FUNDS MANAGEMENT LTD. | 671,644 | $12,291,085 | 2.64% |
| First Light Asset Management, LLC | 1,329,313 | $24,326,428 | 2.26% |
| BRAIDWELL LP | 3,469,674 | $63,495,034 | 2.13% |
| BVF INC/IL | 2,736,613 | $50,080,018 | 2.11% |
| Perceptive Advisors | 4,039,276 | $73,918,751 | 2.08% |